Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Davidson

Showing results (1111-1120 of 1,190) with videos related to

Pageof 119
Sort By:
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
British Journal of Cancer|November 15, 2000
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cellsE van der Wall, T Horn, E Bright, et al.
Plos Genetics|May 7, 2024
Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated diseaseNihar Bhattacharyya, Niuzheng Chai, Nathaniel J Hafford-Tear, et al.
Investigative Ophthalmology & Visual Science|March 20, 2012
Recessive mutations in TSPAN12 cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR)James A Poulter, Alice E Davidson, Manir Ali, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Pageof 119

Showing results (1111-1120 of 1,190) with videos related to

Sort By:
Pageof 119
JAMA Oncology|January 10, 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast CancerWendy A Woodward, William E Barlow, Reshma Jagsi, et al.
British Journal of Cancer|November 15, 2000
Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cellsE van der Wall, T Horn, E Bright, et al.
Plos Genetics|May 7, 2024
Deciphering novel TCF4-driven mechanisms underlying a common triplet repeat expansion-mediated diseaseNihar Bhattacharyya, Niuzheng Chai, Nathaniel J Hafford-Tear, et al.
Investigative Ophthalmology & Visual Science|March 20, 2012
Recessive mutations in TSPAN12 cause retinal dysplasia and severe familial exudative vitreoretinopathy (FEVR)James A Poulter, Alice E Davidson, Manir Ali, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialEdith A Perez, Monica M Reinholz, David W Hillman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2008
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17J N Ingle, D Tu, J L Pater, et al.
Pageof 119